NasdaqGM:JANXBiotechs
Janux Therapeutics (JANX) Narrows Quarterly Losses, Is The Premium Valuation Too Rich?
Janux Therapeutics (JANX) stock is in focus after the company reported second quarter 2026 results, with net loss narrowing to US$21.97 million and basic loss per share from continuing operations at US$0.35.
See our latest analysis for Janux Therapeutics.
The latest earnings update appears to be feeding into a shift in how investors view Janux Therapeutics, with the share price at US$16.26 and a 90 day share price return of 17.74%, alongside a 3 year total shareholder return of 43.77% that...